On October 22, AKESO fell 3.29% in Regular Trading, trading at HK$89.2, with turnover of HK$139 million.
The clearest recent catalyst is the completed share placement, after which the stock has been giving back gains as the market refocuses on dilution despite near-term funding uncertainty being eased.
Company disclosures show AKESO completed the placement of 20 million new shares at HK$97.76 each, raising net proceeds of about HK$1.941 billion. The new shares represent about 2.13% of enlarged share capital, and the proceeds are mainly intended to support core pipeline R&D, clinical work, commercialization, and general corporate purposes. Earlier reports had noted a positive reaction once the financing was completed, but the latest move suggests investors remain sensitive to dilution and valuation after the prior volatility. For context, AKESO reported first-half revenue of RMB1.806 billion, up 27.92%, while net loss narrowed to RMB447 million, reflecting continued heavy R&D investment.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments